

GLOBAL BIOTECH RANDOMIZED 40% OF THE TARGET POPULATION IN 1/3 OF TRADITIONAL RECRUITMENT TIME

Trialbee's Smart Patient Matching saves 3 months in recruitment efforts

Challenge

A global biotech initiated a phase IIb orphan drug study for the treatment of chronic ulcerative colitis.

Study protocol originally accounted for randomizing 120 patients across 40 investigator sites in six EU countries. Full enrollment was expected after 14 months of campaigning.

However, after deploying traditional recruitment methods, the sponsor met only 60% of its patient enrollment target, and extended the recruitment window an additional six months.

Solution

Trialbee partnered with the biotech to close the enrollment gap and move the study forward as planned.

Highly-targeted patients from the public domain that were a good match for this rare disease study were easily identified using real-time analytics driven by Trialbee's Smart Patient Matching solution. Patients who qualified via an online questionnaire were subsequently screened by telephone by a professionally-trained, multilingual nurse panel to ensure each respective patient was indeed a high-quality referral suitable for randomization.

Study overview

- Phase IIb study for severe chronic ulcerative colitis
- 40 investigator sites across 6 EU countries
- 120 patient-randomization target
- 14-month targeted recruitment timeline

Outcome

- Randomized 40% of target population in only 1/3 of the full recruitment period
- Saved 3 months of recruitment efforts
- 165 patients referred through Trialbee


Outcomes

Deploying Trialbee resulted in a 3-month savings in recruitment efforts. 40% of patients were randomized in just 1/3 of the full recruitment period.

Original projections estimated 12 months to enroll the required number of patients using traditional methods. However, the biotech enrolled less than 50 patients after 10 months, and extended its enrollment timeline to 19 months.

Trialbee partnered with the biotech to implement digital campaigning and get recruitment on track. The study met its enrollment target in 16 months, saving 3 months of recruitment efforts. However, if Trialbee had been deployed at study start, the biotech could have enrolled patients in 11 months, saving over 5 months of recruitment efforts.

Additionally, site burden was reduced through e-screening and nurse panel evaluations of referred patients. Only highly-qualified patients were referred and activated at each site, freeing site staff to focus on mission-critical tasks and enabling a superior experience for sites and patients.



40% patients randomized in 1/3 of traditional recruitment period

3 months savings of recruitment time

165 patients referred
120 patients randomized and enrolled

Trialbee Smart Patient Matching

Seamless patient recruitment experience powered by real-time analytics. For more information or to schedule a demo, email us at solutions@trialbee.com or visit us at trialbee.com.